Published in Surgery on September 01, 1993
Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg (1996) 2.24
Translational approaches to treatment-induced symptoms in cancer patients. Nat Rev Clin Oncol (2012) 1.38
Active Negative Pressure Peritoneal Therapy After Abbreviated Laparotomy: The Intraperitoneal Vacuum Randomized Controlled Trial. Ann Surg (2015) 0.93
Pain following the repair of an abdominal hernia. Surg Today (2009) 0.93
Liver failure induces a systemic inflammatory response. Prevention by recombinant N-terminal bactericidal/permeability-increasing protein. Am J Pathol (1995) 0.86
Thoracic duct in patients with multiple organ failure: no major route of bacterial translocation. Ann Surg (1999) 0.86
Anti-inflammatory role of glycine in reducing rodent postoperative inflammatory ileus. Neurogastroenterol Motil (2010) 0.85
Laparoscopic surgery induced interleukin-6 levels in serum and gut mucosa: implications of peritoneum integrity and gas factors. Surg Endosc (2008) 0.85
Changes in endotoxin-binding proteins during major elective surgery: important role for soluble CD14 in regulation of biological activity of systemic endotoxin. Clin Diagn Lab Immunol (1999) 0.83
Acute inflammatory response after inguinal and incisional hernia repair with implantation of polypropylene mesh of different size. Langenbecks Arch Surg (2005) 0.82
Early post-operative interleukin-6 and tumor necrosis factor-α levels after single-port laparoscopic varicocelectomy in children. Pediatr Surg Int (2011) 0.81
Bactericidal/permeability-increasing protein preserves leukocyte functions after major liver resection. Ann Surg (2000) 0.81
Influence of modest endotoxemia on postoperative antithrombin deficiency and circulating secretory immunoglobulin a levels. Ann Surg (2003) 0.78
Elevated NLR in gallbladder cancer and cholangiocarcinoma - making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium. HPB (Oxford) (2016) 0.77
Frequency and yield of postoperative fever evaluation. Infect Dis Obstet Gynecol (1998) 0.77
Comparison of postoperative surgical stress following robotic thyroidectomy and open thyroidectomy: a prospective pilot study. Surg Endosc (2016) 0.76
Postoperative fever predicts poor prognosis of gastric cancer. Oncotarget (2017) 0.75
Prognostic impacts of postoperative complications in patients with intrahepatic cholangiocarcinoma after curative operations. Int J Clin Oncol (2017) 0.75
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med (1997) 10.67
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ (1998) 6.07
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med (1992) 5.48
Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci (1975) 5.23
Travel and risk of venous thrombosis. Lancet (2000) 5.23
Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet (1995) 5.10
Once versus thrice daily gentamicin in patients with serious infections. Lancet (1993) 4.92
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 4.39
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet (1992) 4.15
Increased plasma levels of interleukin-6 in sepsis. Blood (1989) 3.92
Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med (1992) 3.74
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost (2007) 3.66
Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol (1988) 3.51
Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med (1996) 3.42
Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med (1997) 3.26
Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol (1994) 3.22
Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. J Periodontol (2000) 3.03
Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med (1995) 2.98
Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. Lancet (2001) 2.94
A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet (1999) 2.88
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Molecular and quantitative analysis of helper T cell-replacing factors on the induction of antigen-sensitive B and T lymphocytes. J Immunol (1979) 2.79
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet (1999) 2.77
Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med (1989) 2.73
Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet (1988) 2.67
Interleukin 6 is involved in interleukin 1-induced activities. Eur J Immunol (1988) 2.63
Molecular cloning and expression of hybridoma growth factor in Escherichia coli. J Immunol (1987) 2.59
Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet (2000) 2.49
Serum levels of interleukin-6 and acute phase responses. Lancet (1987) 2.44
A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med (1993) 2.39
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol (2000) 2.35
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood (1990) 2.33
Activation of coagulation system during air travel: a crossover study. Lancet (2006) 2.32
FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity (2002) 2.31
Mortality in hereditary antithrombin-III deficiency--1830 to 1989. Lancet (1991) 2.31
Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. Clin Exp Immunol (1988) 2.24
Meta-analysis: the final answer, or even more confusion? Lancet (1996) 2.24
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum (1979) 2.23
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21
Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol (2001) 2.20
Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet (1997) 2.20
Limitations of compression ultrasound for the detection of symptomless postoperative deep vein thrombosis. Lancet (1994) 2.18
Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost (1999) 2.18
High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost (2000) 2.15
Procoagulant and proinflammatory activity in acute coronary syndromes. Cardiovasc Res (1998) 2.12
Regulatory properties of LFA-1 alpha and beta chains in human T-lymphocyte activation. Nature (1988) 2.09
Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences. J Thromb Haemost (2006) 2.06
[Atherosclerosis partly due to local vasculitis]. Ned Tijdschr Geneeskd (1994) 2.05
On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest (1992) 2.04
[Optimal treatment with oral anticoagulants]. Ned Tijdschr Geneeskd (1996) 2.03
Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. J Infect Dis (2000) 2.00
Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med (1999) 2.00
Deep-vein thrombosis. Lancet (1999) 1.98
Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. J Thromb Haemost (2013) 1.97
Application of treatment thresholds to diagnostic-test evaluation: an alternative to the comparison of areas under receiver operating characteristic curves. Med Decis Making (1997) 1.96
The purification and quantitation of helper T cell-replacing factors secreted by murine spleen cells activated by concanavalin A. J Immunol (1979) 1.95
Compression ultrasonography of the leg veins in patients with clinically suspected pulmonary embolism: is a more extensive assessment of compressibility useful? Thromb Haemost (2000) 1.95
Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med (1999) 1.95
Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol (2001) 1.95
HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut (1999) 1.94
Activation of interleukin-2 gene transcription via the T-cell surface molecule CD28 is mediated through an NF-kB-like response element. J Biol Chem (1991) 1.92
Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA (1993) 1.88
Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun (1992) 1.85
Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am (1999) 1.82
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med (1999) 1.81
A growth-factor dependent B-cell hybridoma. Curr Top Microbiol Immunol (1986) 1.79
Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation (1992) 1.78
Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med (1990) 1.76
Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet (1994) 1.76
The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun (1988) 1.76
An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun (1999) 1.75
Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. J Immunol (1996) 1.74
Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis (1992) 1.73
Comparison of a clinical probability estimate and two clinical models in patients with suspected pulmonary embolism. ANTELOPE-Study Group. Thromb Haemost (2000) 1.73
Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet (1992) 1.73
A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med (2001) 1.72
Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med (1996) 1.70
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost (2005) 1.70
Proinflammatory effects of IL-10 during human endotoxemia. J Immunol (2000) 1.69
Bacterial translocation in multiple organ failure: cause or epiphenomenon still unproven. Br J Surg (1997) 1.69
Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost (2006) 1.69
Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr (2001) 1.68